IKT Graph | Inhibikase Therapeutics, Inc.

IKT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $0.00; Research and development $13.39M; Selling, general and administrative $7.66M; Income tax $0.00.
2026-03-31: Revenue $0.00; Research and development $10.84M; Selling, general and administrative $7.38M; Income tax $0.00.
2025-12-31: Revenue (m); Research and development $6.36M*; Selling, general and administrative $6.77M*; Income tax $0.00*.
2025-09-30: Revenue $0.00; Research and development $7.65M; Selling, general and administrative $5.61M; Income tax $0.00.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$0.00	$13.39M	$7.66M	$0.00	-$19.59M
2026-03-31	$0.00	$10.84M	$7.38M	$0.00	-$16.38M
2025-12-31	(m)	$6.36M*	$6.77M*	$0.00*	-$12.74M*
2025-09-30	$0.00	$7.65M	$5.61M	$0.00	-$11.93M
2025-06-30	$0.00	$5.27M	$5.92M	$0.00	-$9.92M
2025-03-31	$0.00	$10.51M	$5.25M	$0.00	-$13.68M
2024-09-30	$0.00	$4.19M	$1.64M	$0.00	-$5.78M
2024-06-30	$0.00	$3.08M	$1.97M	$0.00	-$4.96M
2024-03-31	$0.00	$2.75M	$2.03M	$0.00	-$4.65M
2023-09-30	$79.57K	$3.23M	$1.62M	$0.00	-$4.60M
2023-06-30	$116.41K	$4.54M	$1.78M	$0.00	-$5.78M
2023-03-31	$64.52K	$2.85M	$1.93M	$0.00	-$4.48M
2022-09-30	$7.29K	$2.98M	$1.54M	$0.00	-$4.49M
2022-06-30	$6.55K	$2.98M	$1.66M	$0.00	-$4.64M
2022-03-31	$46.03K	$3.02M	$1.67M	$0.00	-$4.64M
2021-09-30	$328.46K	$3.15M	$1.64M	(m)	-$4.47M
2021-06-30	$1.36M	$2.38M	$1.61M	(m)	-$2.64M
2021-03-31	$1.41M	$2.43M	$1.60M	$0.00	-$2.64M
2020-09-30	$37.68K	$120.57K	$580.82K	(m)	-$670.60K
2020-06-30	$219.59K	$263.18K	$370.33K	(m)	-$421.87K
2020-03-31	$270.79K	$283.11K	$527.69K	$0.00	-$547.44K

Revenue and expense 6 month

Period end	Revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$0.00	$24.23M	$15.03M	$0.00	-$35.97M
2025-06-30	$0.00	$15.78M	$11.17M	$0.00	-$23.59M
2024-06-30	$0.00	$5.83M	$4.01M	$0.00	-$9.61M
2023-06-30	$180.93K	$7.39M	$3.71M	$0.00	-$10.26M
2022-06-30	$52.58K	$6.00M	$3.33M	$0.00	-$9.28M
2021-06-30	$2.77M	$4.81M	$3.21M	$0.00	-$5.27M
2020-06-30	$490.37K	$546.29K	$898.02K	$0.00	-$969.31K

Revenue and expense 9 month

Period end	Revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-09-30	$0.00	$23.43M	$16.78M	$0.00	-$35.52M
2024-09-30	$0.00	$10.02M	$5.64M	$0.00	-$15.39M
2023-09-30	$260.50K	$10.62M	$5.33M	$0.00	-$14.85M
2022-09-30	$59.87K	$8.98M	$4.87M	$0.00	-$13.78M
2021-09-30	$3.10M	$7.97M	$4.85M	$0.00	-$9.74M
2020-09-30	$528.05K	$666.86K	$1.48M	$0.00	-$1.64M

Revenue and expense 12 month

Period end	Revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-12-31	(m)	$29.79M	$23.56M	$0.00	-$48.26M
2024-12-31	$0.00	$17.21M	$11.38M	$0.00	-$27.52M
2023-12-31	$260.50K	$13.62M	$6.73M	(m)	-$19.03M
2022-12-31	$123.44K	$12.03M	$6.22M	(m)	-$18.05M
2021-12-31	$3.10M	$11.36M	$6.51M	(m)	-$14.79M
2020-12-31	$698.47K	$893.80K	$2.62M	(m)	-$2.85M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Ocugen, Inc. (OCGN)	United States	$0.343B	-6.34